The Remel Xpect® clostridium difficile toxin A/B test can now be used with specimens transported at room temperature for up to 5 days in modified Cary Blair transport medium (or equivalent). The new specimen-transport option increases flexibility in the lab and reduces time and labor in specimen preparation. The Xpect C. difficile Toxin A/B test is the only rapid test to combine the detection of toxin A and B with excellent clinical performance, flexible specimen-transport options, and a “walkaway” test procedure that provides results within 20 minutes. The Xpect C. difficile Toxin A/B test kit is a rapid in vitro immunochromatographic test for the direct, qualitative detection of Clostridium difficile Toxin A and/or B in human fecal specimens from patients suspected of having Clostridium difficile-associated disease (CDAD). C. difficile typically affects older or severely ill patients in hospitals or residents of long-term-care facilities. Recent reports from the Centers for Disease Control and Prevention (CDC) acknowledge that both the frequency and severity of health care-associated CDAD have increased. In addition, an epidemic strain with special virulence and antimicrobial resistance properties and a community-associated CDAD has emerged; therefore, accurate, rapid testing for C. difficile is important improved patient management.

Remel Inc
(800) 255-6730; www.remel.com